Market Shockwaves from Trump's Tariff Plans

In a surprising move that sent shockwaves through the European pharmaceutical sector, US President Donald Trump announced plans to impose a "major tariff" on pharmaceuticals. This announcement led to a significant drop in the stocks of leading European pharmaceutical companies, including Sanofi, GSK, AstraZeneca, Roche, and Novartis.

Immediate Impact on Stock Prices

By mid-morning CET, the financial repercussions were starkly evident. Novartis AG and Roche Holding AG saw their shares plummet by 7.03% and 5.80%, respectively. Similarly, Sanofi SA, AstraZeneca PLC, and GSK plc experienced notable declines, with their stock prices falling sharply in response to the news.

Investor Concerns Grow

The tariff announcement has raised concerns among investors about the potential ripple effects on the global pharmaceutical market. The immediate stock price drops reflect the market's nervous anticipation of how these tariffs could reshape trade dynamics and profitability in the sector.